مقالات علمی

مقالات علمی

Evaluation of the rate of COVID-19 infection, hospitalization and death
among Iranian patients with multiple sclerosis

_

Background: COVID-19 is increasingly expanding all over the world. People who have an underlying disease or taking immunosuppressive drugs are generally more likely to be infected than the others. Multiple sclerosis (MS) patients may also be at risk of the disease and its complications depending on the medication they are taking. In this study, we evaluated a large population of patients with MS with different disease modifying drugs to show if any of them increases the risk. In addition, this study evaluates the incidence of COVID-19 in patients with MS, the rate of hospitalization or death in these patients.

Knowledge regarding COVID-19 pandemic in patients with multiple
sclerosis (MS): A report from Iran

_

n December 2019, a novel coronavirus was introduced, causing
viral pneumonia and severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (Wang et al., 2020). The outbreak spread from China to
24 other countries within a few weeks (Johns Hopkins CSSE Wc-ngcO
2020).

The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19
era

_

Multiple sclerosis (MS) is recognized as a demyelinating disease of the central
nervous system through autoimmune involvement of the brain and spinal cord (1-4). Evans
syndrome is an uncommon autoimmune disorder

Is anemia a probable cause of fatigue in
?patients with multiple sclerosis

_

Fatigue, in many studies, has been identified as the
most common complaint of patients with Multiple
Sclerosis (MS); it can have a negative impact on
different aspects of their life.1

جهت مشاهده و دانلود مقالات دکتر عبدالرضا ناصر مقدسی به سایت زیر مراجعه نمایید.

Papers
_

English Papers:

_

1. Seyed Ahadi M, Sahraian MA, Baghbanian SM, Azimi A, Shaygannejad V, Anjidani N, Naser Moghadasi A, et al. Pregnancy outcome in patients with multiple sclerosis treated with Rituximab: A case-series study. Multiple Sclerosis and Related Disorders. 2021;47.

2.  Sahraian MA, Gheini MR, Rezaeimanesh N, Ghajarzadeh M, Naser Moghadasi A. Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran. Multiple Sclerosis and Related Disorders. 2020;42.

3. Sahraian MA, Azimi A, Navardi S, Rezaeimanesh N, Naser Moghadasi A. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran. Multiple Sclerosis and Related Disorders. 2020;44.
4.Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Multiple Sclerosis and Related Disorders. 2020;46.
5.Rezaeimanesh N, Sahraian MA, Moghadasi AN, Eskandarieh S. Epidemiology of neuromyelitis optica spectrum disorder in Tehran, Iran: the prevalence, baseline characteristics, and clinical aspects. Neurological Sciences. 2020;41(9):2647-8.
6. Rezaeimanesh N, Saeedi R, Sahraian MA, Razeghi Jahromi S, Naser Moghadasi A. The possible beneficial effects of higher vitamin B6 intake from diet on cognitive function of patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders. 2020;42.
7. Ramezani N, Yarahmadi P, Alirezaei M, Forouzannia SM, Kazemi Mozdabadi RS, Rezaei Aliabadi H, Naser Moghadasi A, et al. Evaluation of emotional intelligence (EI) in neuromyelitis optica spectrum disorder (NMOSD) patients compared to healthy individuals. Multiple Sclerosis and Related Disorders. 2020;45.
8.Navardi S, Sahraian MA, Naser Moghadasi A. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report. Revue Neurologique. 2020;176(4):289-90.
9. Naser Moghadasi A, Sahraian MA. Aggressive course of cognitive impairment in multiple sclerosis: A new term for the management of patients. Journal of Clinical Neuroscience. 2020;71:308-10.
10.  Naser Moghadasi A. Environmental and genetic risk factors in the development of neuromyelitis optica. Expert Review of Ophthalmology. 2020;15(1):1-9.
11.  Naser Moghadasi A. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients. Multiple Sclerosis and Related Disorders. 2020;41.
12. Naser Moghadasi A. The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era. Multiple Sclerosis and Related Disorders. 2020;42.
13. Naser Moghadasi A. The role of the brain in the treatment of multiple sclerosis as a connectomopathy. Medical Hypotheses. 2020;143.
14. Naser Moghadasi A. Neural implant for the treatment of multiple sclerosis. Medical Hypotheses. 2020;145.
15. Naser Moghadasi A. Encephalopathy associated with COVID-19 in a patient with multiple sclerosis. Journal of NeuroVirology. 2020;26(6):973-5.
16. Moghadasi AN. Evaluation of the level of anxiety among iranian multiple sclerosis fellowships during the outbreak of COVID-19. Archives of Iranian Medicine. 2020;23(4):283.
17. Moghadasi AN. Progressive myelopathy in a patient with pediatric onset neuromyelitis optica spectrum disorder: A case report and a mini review. Acta Neurologica Taiwanica. 2020;29(1):1-4.
18. Moghadasi AN. History of multiple sclerosis in Iran. Archives of Iranian Medicine. 2020;23(3):211-5.
19. Moghadasi AN. Opportunities and threats: The necessity of research in dealing with the rapid spread of coronavirus disease 2019 (COVID-19) in Iran. Archives of Clinical Infectious Diseases. 2020;15(COVID-19).
20.  Haji Akhoundi F, Sahraian MA, Naser Moghadasi A. Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2020;41.
21. Ghiasian M, Nouri M, Moghadasi AN, Ghaffari M. Effect of pregnancy and exclusive breastfeeding on multiple sclerosis relapse rate and degree of disability within two years after delivery. Clinical Neurology and Neurosurgery. 2020;194.
22. Ebadi Z, Saeedi R, Hashemi SN, Gheini MR, Sahraian MA, Naser Moghadasi A. Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD). Multiple Sclerosis and Related Disorders. 2020;42.
23. Azadvari M, Razavi SZE, Shahrooei M, Moghadasi AN, Azimi A, Farhadi-Shabestari HR. Bladder dysfunction in iranian patients with multiple sclerosis. Journal of Multidisciplinary Healthcare. 2020;13:345-9.
24. Azadvari M, Naser Moghadasi A, Azimi AR, Sharifiaghdas F, Emami Razavi SZ, Eskandarieh S, et al. Persian adaptation of actionable bladder symptom screening tool among patients with multiple sclerosis. Journal of Multidisciplinary Healthcare. 2020;13:79-83.
25. Ahadi MS, Sahraian MA, Rezaeimanesh N, Moghadasi AN. Psychiatric advice during Covid-19 pandemic for patients with multiple sclerosis. Iranian Journal of Psychiatry and Behavioral Sciences. 2020;14(2).
26. Ahadi MS, Moghadasi AN, Asgari N, Sahraian MA. Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases. Caspian Journal of Internal Medicine. 2020;11(2):155-62.
27. Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, et al, Naser Moghadasi A. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Multiple Sclerosis and Related Disorders. 2019;27:350-63.
28.  Shahin S, Eskandarieh S, Moghadasi AN, Razazian N, Baghbanian SM, Ashtari F, et al. Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set. Multiple Sclerosis and Related Disorders. 2019;33:158-61.
29. Sahraian MA, Mohyeddin Bonab M, Baghbanian SM, Owji M, Naser Moghadasi A. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection. Immunological Investigations. 2019;48(2):160-8.
30. Sahraian MA, Ghiasian M, Moghadasi AN, Shafaei M, Ghaffari M. Progressive solitary sclerosis presented with diplopia: A case report. Multiple Sclerosis and Related Disorders. 2019;28:129-31.
31. Roostaei T, Sadaghiani S, Mashhadi R, Falahatian M, Mohamadi E, Javadian N, Naser Moghadasi A, et al. Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal. 2019;25(4):532-40.
32. Rezaeimanesh N, Razeghi Jahromi S, Naser Moghadasi A, Rafiee P, Ghorbani Z, Beladi Moghadam N, et al. Dietary total antioxidant capacity and neuromyelitis optica spectrum disorder susceptibility. Nutrition and Food Science. 2019;50(4):653-63.
33. Rezaeimanesh N, Razeghi Jahromi S, Ghorbani Z, Beladi Moghadam N, Hekmatdoost A, Naser Moghadasi A, et al. The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case–control study. Multiple Sclerosis and Related Disorders. 2019;31:112-7.
34. Owji M, Ashraf-Ganjouei A, Sahraian MA, Bidadian M, Ghadiri F, Naser Moghadasi A. The relationship between cognitive function and body mass index in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2019;32:37-40.
35. Noori H, Gheini MR, Rezaeimanesh N, Saeedi R, Rezaei Aliabadi H, Sahraian MA, Naser Moghadasi A, et al. The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2019;36.
36. Naser Moghadasi A, Darki A, Masoumi P, Hashemi SN, Ghadiri F. Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. Multiple Sclerosis and Related Disorders. 2019;36.
37. Naser Moghadasi A. Corpus callosum agenesis and clinically isolated syndrome (CIS): A case report. Multiple Sclerosis and Related Disorders. 2019;27:342-3.
38. Naser Moghadasi A. Bilateral extensive lesions of the brain in a patient with neuromyelitis optica manifested with seizure and cognitive impairments. Revue Neurologique. 2019;175(4):272-4.
39. Naser Moghadasi A. Burnt City and the Evolution of Cognitive Science. Archives of Iranian medicine. 2019;22(8):480-1.
40. Naser Moghadasi A. When an octopus has MS: Application of neurophysiology and immunology of octopuses for multiple sclerosis. Medical Hypotheses. 2019;131.
41. Naser Moghadasi A. The Oldest Image of a Woman During Vaginal Delivery in the Continental Shelf of Iran. Archives of Iranian medicine. 2019;22(10):631-2.
42. Moghadasi AN, Baghbanian SM. Neuromyelitis optica spectrum disorder with radiological manifestation of multiple sclerosis in the first brain MRI: A case report. Future Neurology. 2019;14(2).
43. Moghadasi AN, Baghbanian SM. Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab. Acta Neurologica Belgica. 2019;119(1):137-9.
44. Moghadasi AN. Lack of attention to epidemiological study of neuromyelitis optica spectrum disorder compared with that of multiple sclerosis in Iran. International Journal of MS Care. 2019;21(6):281.
45. Eskandarieh S, Sahraiain MA, Molazadeh N, Moghadasi AN. Pediatric multiple sclerosis and its familial recurrence: A population based study (1999–2017). Multiple Sclerosis and Related Disorders. 2019;36.
46. Baghbanian SM, Sahraian MA, Naser Moghadasi A, Asgari N. Disability and therapeutic response in paediatric neuromyelitis optica spectrum disorder a case series from Iran. Iranian Journal of Child Neurology. 2019;13(3):99-104.
47. Azimi M, Ghabaee M, Moghadasi AN, Izad M. Altered expression of miR-326 in T cell-derived exosomes of patients with relapsing-remitting multiple sclerosis. Iranian Journal of Allergy, Asthma and Immunology. 2019;18(1):108-13.
48. Asadi-Pooya AA, Sahraian MA, Sina F, Baghbanian SM, Habibabadi JM, Shaygannejad V, Naser Moghadasi A, et al. Management of seizures in patients with multiple sclerosis; an Iranian consensus. Epilepsy and Behavior. 2019;96:244-8.
49. Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Abdorreza Naser Moghadasi*, et al. Autoimmune diseases associated with Neuromyelitis Optica spectrum disorders: A literature review. Multiple Sclerosis and Related Disorders. 2018.
50. Moghadasi AN. Corpus Callosum Agenesis and Clinically Isolated Syndrome (CIS): A Case Report. Multiple Sclerosis and Related Disorders. 2018.
51. Arzani, M., H. Rezaei, and A.N. Moghadasi, Association of limb-girdle muscular dystrophy with multiple sclerosis: A case report. Caspian Journal of Internal Medicine, 2018. 9(1): p. 96-99.
52. Azimi, M., A.N. Moghadasi, et al., Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis. Immunologic Research, 2018. 66(4): p. 513-520.
53. Baghbanian, S.M., A.N. Moghadasi et al., A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. Journal of the Neurological Sciences, 2018. 388: p. 222-231.
54. Baghbanian, S.M. and A.N. Moghadasi, Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis. Iran J Neurol, 2018. 17(2): p. 89-90.
55. Darki, A., A.N. Moghadasi, et al., Myocardial infarction in a patient with multiple sclerosis after receiving natalizumab. Multiple Sclerosis and Related Disorders, 2018. 25: p. 26-28.
56. Doosti, R., A.N. Moghadasi, et al., Evaluation of the risk of cervical cancer in patients with Multiple Sclerosis treated with cytotoxic agents: A cohort study. Iran J Neurol, 2018. 17(2): p. 64-70.
57. Eskandarieh, S., A.N. Moghadasi, et al., The prevalence, incidence and familial recurrence of multiple sclerosis in Tehran, Iran. Multiple Sclerosis and Related Disorders, 2018. 25: p. 143.
58. Eskandarieh, S., A.N. Moghadasi, et al. Environmental risk factors in neuro myelitis optica. in MULTIPLE SCLEROSIS JOURNAL. 2018. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND.
59. Ghajarzadeh, M., A.N. Moghadasi, et al., Pain in Patients with Multiple Sclerosis. Maedica (Buchar), 2018. 13(2): p. 125-130.
60. Jafari, Z., A.N. Moghadasi, et al., The validation of the Persian version of DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Iranian Journal of Neurology, 2018. 17(3).
61. Koolaji, S., A.N. Moghadasi, et al., Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. Journal of NeuroVirology, 2018: p. 1-7.
62. Mehrpour, M., A.N. Moghadasi, et al., Serum Anti-Mullerian Hormonelevels in Multiple Sclerosis; a Multicenter Case-Control Study. Česká a slovenská neurologie a neurochirurgie, 2018. 81(2).
63. Moghadasi, A.N., Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria? Multiple sclerosis and related disorders, 2018. 20: p. 153.
64. Moghadasi, A.N. and S.M. Baghbanian, Tumefactive demyelinating lesions in a patient with multiple sclerosis receiving natalizumab. Acta Neurologica Belgica, 2018: p. 1-3.
65. Mousavi Nasl-khameneh, A., A.N. Moghadasi et al., Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORγt gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis. Neurological Research, 2018. 40(1): p. 11-17.
66. Naser Moghadasi, A., Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria? Multiple Sclerosis and Related Disorders, 2018. 20: p. 153.
67. Nasl-Khameneh, A.M., A.N. Moghadasi et al., Comparison of cytokine expression in multiple sclerosis patients and healthy volunteers. Acta Medica Iranica, 2018. 56(2): p. 77-83.
68. Ouspid, E., A.N. Moghadasi et al., Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran. Neurosciences, 2018. 23(2): p. 129-134.
69. Owji, M., A.N. Moghadasi et al., Evaluating the relationship between emotional intelligence and cognitive disorders in patients with Multiple Sclerosis. Iran J Neurol, 2018. 17(2): p. 78-81.
70. Roostaei, T., A.N. Moghadasi et al., Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2018: p. 1352458518760715.
71. Sahraian, M.A., A.N. Moghadasi et al., Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection. Immunological Investigations, 2018.
72. Shahmohammadi, S., A.N. Moghadasi et al., A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Multiple Sclerosis and Related Disorders, 2018. 22: p. 22-26.
73. Tavakolpour, V., A.N. Moghadasi et al., Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity. Journal of Neuroimmunology, 2018.
74. Zarrinkoob, H., A.N. Moghadasi et al., Validity and reliability of Persian version of activities-specific balance confidence scale in patients with multiple sclerosis. Auditory and Vestibular Research, 2017. 26(2): p. 64-70.
75. Arzani, M., A.N. Moghadasi, et al., Recurrent isolated optic neuritis: A study on 22 patients. Iran J Neurol, 2017. 16(3): p. 130-135.
76. Baghbanian, S.M. and A. Naser Moghadasi, Optic neuritis in a patient with celiac disease. Neurologia i Neurochirurgia Polska, 2017. 51(6): p. 534-536.
77. Bitarafan, S., A.N. Moghadasi, et al., The first attack of multiple sclerosis presented immediately after voluntary and intensive weight loss: A case series. Iran J Neurol, 2017. 16(1): p. 41-42.
78. Eskandarieh, S., A.N. Moghadasi, et al., Risk Factors of Multiple Sclerosis and Neuromyelitis Optica. Multiple Sclerosis Journal, 2017. 23(2): p. 321-321.
79. Eskandarieh, S., A.N. Moghadasi, et al., Comparing epidemiology and baseline characteristic of multiple sclerosis and neuromyelitis optica: A case-control study. Multiple Sclerosis and Related Disorders, 2017. 12: p. 39-43.
80.Eskandarieh, S., A.N. Moghadasi, et al., Neuromyelitis optica spectrum disorders in Iran. Multiple Sclerosis and Related Disorders, 2017. 18: p. 209-212.
81. Moghadasi, A.N., Optic neuritis with radiological longitudinal spinal cord involvement and seronegative anti-aquaporin antibody: Evidence from a case study. Multiple sclerosis and related disorders, 2017. 18: p. 26-28.
82. Moghadasi, A.N. NEUROMYTHOLOGY: RELATIONSHIP BETWEEN BRAIN, EVOLUTION, AND MYTHOLOGY. EXPRESSION, 2017.
83. Moghadasi, A.N. and S. Salehizadeh, Endometriosis in a patient with multiple sclerosis receiving mitoxantrone: a case study. Archives of Neuroscience, 2017. 4(1).
84. Okhovat, A.A., A.N. Moghadasi et al., Catastrophic presentation of a patient with combined NMOSD and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a case report. Acta Neurologica Belgica, 2017. 117(3): p. 757-759.
85.Sahraian, M.A., A.N. Moghadasi et al., Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. Mult Scler Relat Disord, 2017. 18: p. 144-151.
86. Sahraian, M.A., A.N. Moghadasi et al., Sleep disorder as a triggering factor for relapse in multiple sclerosis. European Neurology, 2017. 77(5-6): p. 258-261.
87. Shahmohammadi, A.N. Moghadasi S., et al., Intracerebral Hemorrhage in a Patient with Multiple Sclerosis Receiving Interferon Beta-1α. Archives of Neuroscience, 2017. 4(2).
88. Shirvani-Farsani, A.N. Moghadasi Z., et al., The expression of VDR mRNA but not NF-κB surprisingly decreased after vitamin D treatment in multiple sclerosis patients. Neuroscience Letters, 2017. 653: p. 258-263.
89. Cheraghmakani, H., M. Abedini, and A.N. Moghadasi, Hashimoto Encephalopathy with Sensory Polyneuropathy: A Case Report. Case Reports in Clinical Practice, 2016. 1(1): p. 11-14.
90. Ghajarzadeh, M., A.N. Moghadasi, et al., Validity and reliability of the persian version of the PERception de la scle’rose en plaques et de ses pousse’es questionnaire evaluating multiple sclerosis-related quality of life. International Journal of Preventive Medicine, 2016. January-2016.
91. Gholinejad, K., A.N. Moghadasi, et al., Anti–MBP autoantibody changes as a predictor of response to treatment in MS patients. Journal of Paramedical Sciences, 2016. 7(2): p. 1-7.
92. Haghighi, S., M. Seyed Ahadi, and A. Naser Moghadasi, Cryptococcal meningitis in a human immunodeficiency virus-negative patient with rheumatoid arthritis. Iran J Neurol, 2016. 15(2): p. 106-8.
93. Moghadasi, A.N., S. Advani, and S. Rahimi, Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri. Iran J Neurol, 2016. 15(3): p. 175-6.
94. Moghadasi, A.N. and A. Altintas, NMOSD with an unusual cerebral radiologic manifestation. Multiple Sclerosis and Related Disorders, 2016. 7: p. 74-75.
95. Moghadasi, A.N., et al., Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies. Neurologic Clinics, 2016. 34(1): p. 17-31.
96. Roostaei, T., A.N. Moghadasi et al., Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis. Neurology, 2016. 86(5): p. 410-417.
97. Sahraian, M.A., M. Owji, and A. Naser Moghadasi, Concomitant multiple sclerosis and another autoimmune disease: Does the clinical course change? Clinical Neurology and Neurosurgery, 2016. 150: p. 92-95.
98.Togha, M., A.N. Moghadasi et al., Headache in relapse and remission phases of multiple sclerosis: A case-control study. Iranian journal of neurology, 2016. 15(1): p. 1.
99. Moghadasi, A.N., Neurocinema: A brief overview. Iranian journal of neurology, 2015. 14(3): p. 180.
100. Moghadasi, A.N., Compulsion in a different artistic format for a patient with FTD. Acta Neurologica Belgica, 2015. 4(115): p. 707-708.
101. Moghadasi, A.N., Anahita Arәdvī Sūra: The Goddess of Health. Journal of Research on History of Medicine, 2015. 4(1 Feb).
102. Moghadasi, A.N., Mithra’s Brain. Journal of Research on History of Medicine, 2015. 4(3 Aug).
103. Moghadasi, A.N., First Visual Evidence of Leprosy in the Continental Shelf of Iran. Iranian journal of public health, 2015. 44(8): p. 1162.
104. Moghadasi, A.N., The Burnt City and the Evolution of the Concept of “Probability” In the Human Brain. Iranian journal of public health, 2015. 44(9): p. 1306.
105. Moghadasi, A.N., K. Bozorgvari, and M. Arzani, An unusual radiological presentation of posterior reversible encephalopathy syndrome. Neurologia i Neurochirurgia Polska, 2015. 49(3): p. 203-205.
106. Naser Moghadasi, A., Artistic activity from health through disease, then death in a patient with frontotemporal dementia. Neurol Neurochir Pol, 2015. 49(6): p. 472-4.
107. Naser Moghadasi, A., The Burnt City and the Evolution of the Concept of “Probability” In the Human Brain. Iran J Public Health, 2015. 44(9): p. 1306-7.
108. Sahraian, M.A., A.N. Moghadasi et al., Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: A case report. Journal of Medical Case Reports, 2015. 9(1).
109.Shirvani-Farsani, Z., A.N. Moghadasi et al., Vitamin D levels in multiple sclerosis patients: Association with TGF-beta2, TGF-betaRI, and TGF-betaRII expression. Life Sci, 2015. 134: p. 63-7.
110.Motamedi, M., A.N. Moghadasi, et al., Endometriosis of the lumbosacral plexus: report of a case with foot drop and chronic pelvic pain. Acta Neurologica Belgica, 2015. 115(4): p. 851-852.
111. Ghajarzadeh, M., A.N. Moghadasi, et al., Emotional Intelligence (EI) of Patients with Multiple Sclerosis (MS). Iran J Public Health, 2014. 43(11): p. 1550-6.
112. Moghadasi, A.N., Artificial eye in burnt city and theoretical understanding of how vision works. Iranian Journal of Public Health, 2014. 43(11): p. 1595-1596.
113. Moghadasi, A.N., Neuroplasticity in early onset multiple sclerosis. Iranian Journal of Child Neurology, 2014. 8(4): p. 80-81.
114.  Moghadasi, A.N., Tragedy of Rostam and Sohrab: First example introducing the science of Mytho-pathology. Iranian journal of public health, 2014. 43(8): p. 1157.
115. Moghadasi, A.N., First Skull Surgery in Iran: The Burned City and a 4800-Year-Old Skull. Iranian journal of public health, 2014. 43(2): p. 249.
116.  Moghadasi, A.N., Multiple sclerosis in parsis: a historical issue. Iranian journal of public health, 2014. 43(3): p. 387-8.
117. Moghadasi, A.N., Ability to gain religious experiences as a part of cognitive abilities. Iranian journal of neurology, 2014. 13(3): p. 191.
118. Moghadasi, A.N., A Sample of a Mytho-pathologic Study: The Story of Rostam and Esfandiyar. Journal of Research on History of Medicine, 2014. 3(4 Nov).
119.  Moghadasi, A.N., Contentment Drug: An Ancient Persian Text about Happiness. Journal of Research on History of Medicine, 2014. 3(3 Aug).
120.  Moghadasi, A.N., Agnosia in Canon: a Historical Issue. Iranian journal of public health, 2014. 43(6): p. 855-6.
121.  Sarraf, P., A.N. Moghadasi et al., Relationship between sleep quality and quality of life in patients with multiple sclerosis. International journal of preventive medicine, 2014. 5(12): p. 1582.
122. Sahraian, M.A., A.N. Moghadasi et al., Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-β-1b: A case report. Journal of Medical Case Reports, 2013. 7.
123. Togha, M. and A.N. Moghadasi, Iranian neurological events: The 20(th) Iranian Congress of Neurology and Electrophysiology. Iran J Neurol, 2013. 12(3): p. 119-20.
124.   Moghadasi, A.N. and O. Sanaei, Cerebral air emboli. Iran J Neurol, 2013. 12(1): p. 30-1.
125.    Motamedi, M., A.N. Moghadasi, and S.A. Karvigh, Age-related serum vitamin B12 concentrations in epileptic patients receiving valproate monotherapy. Iran J Neurol, 2013. 12(1): p. 37-8.
126.  Rezaali, S., A.N. Moghadasi et al., Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. Iranian journal of neurology, 2013. 12(4): p. 136.
127.  Mir-Reza, S., A.N. Moghadasi, et al., Is anemia a probable cause of fatigue in patients with multiple sclerosis? Iran J Neurol, 2013. 12(1): p. 35-6.
128.  Moghadasi, A.N., et al., Pituitary apoplexy presented with optic neuritis. Iran J Neurol, 2013. 12(3): p. 117-8.
129.  Moghadasi, A.N. and M. Owji, Can multiple sclerosis as a cognitive disorder influence patients’ dreams? Iran J Neurol, 2013. 12(2): p. 75-6.
130.  Moghadasi, A.N., The Use of a Topographic Model to Describe Cognitive Disorders for Patients with Multiple Sclerosis.
131.   Moghadasi, A.N., et al., An Interesting Dream as a Provoking Factor for Relapse in a Patient with Multiple Sclerosis: A Case Report.

132.   Moghadasi, A.N., Brain and Cosmology.